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AbstrACt
Introduction Lipid-lowering drugs and 
antihypertensive agents can be prescribed for the 
primary prevention of cardiovascular disease. In 
some cases, patients eligible for primary prevention 
of cardiovascular disease according to the European 
guidelines are not always started on preventive drugs. 
Existing research explores the attitudes of health 
professionals and patients towards cardiovascular 
preventive drugs but does not always differentiate 
between the attitudes towards drug initiation 
for primary or secondary prevention. We aim to 
systematically review qualitative studies assessing 
health professionals’ and patients’ attitudes and 
perceptions towards drug initiation for primary 
prevention of cardiovascular disease.
Methods and analysis MEDLINE, MEDLINE In Process, 
EMBASE, PsycINFO, CINAHL, Applied Social Sciences 
Index and Abstracts, Conference Proceedings Citation 
Index (Web of Science), Healthcare Management 
Information Consortium, and Open Grey will be 
searched without restrictions on date or language 
of publication. Searches will be limited to studies of 
qualitative design, standalone or in the context of a 
mixed-method design, focusing on cardiovascular 
drug initiation for primary prevention. The primary 
outcome is the attitudes of health professionals 
and patients towards drug initiation for primary 
prevention of cardiovascular disease. Two reviewers 
will independently carry out the study selection, 
data extraction and quality assessment. The Critical 
Appraisal Skills Programme Qualitative Research 
Checklist will be used to assess the quality of included 
studies. The findings will be analysed using Thomas 
and Harden's thematic synthesis approach.
Ethics and dissemination This systematic review does 
not require ethical approval as primary data will not 
be collected. The results of the study will be published 
in a peer-reviewed journal and presented at relevant 
conferences.
PrOsPErO registration number CRD42018095346.
IntrOduCtIOn
Cardiovascular disease (CVD) is the leading 
cause of deaths worldwide.1 It accounts for 
26% of deaths in the UK and 31% of deaths 
globally.1 2 One of the ways to prevent CVD 
is through prescribing drugs for primary 
prevention. National and international 
guidelines recommend primary preventive 
treatment for patients at an increased risk of 
developing a cardiovascular event.3–6 Patients 
considered at an increased risk include 
patients with a clinically measured blood 
pressure of ≥140/90 mm Hg or patients who 
have a 10-year CVD risk of 10% or more.4 6 
A patient's risk of developing CVD within the 
next 10 years can be predicted using a risk 
assessment tool such as QRISK2. The QRISK2 
assessment tool calculates an individual's CVD 
risk taking into account factors such as age, 
ethnicity, smoking status, systolic blood pres-
sure, cholesterol/high-density lipoprotein 
strengths and limitations of this study
 ► This review will use a systematic approach to sum-
marise qualitative evidence on preventive drug initi-
ation in primary care settings.
 ► This review will focus on summarising existing evi-
dence regarding drug initiation for primary preven-
tion of cardiovascular disease as recommended by 
the European guidelines.
 ► It will provide a better understanding of what influ-
ences health professionals’ and patients’ decisions 
regarding initiation of preventive treatment.
 ► The study will not review attitudes towards drug ini-
tiation in secondary or tertiary care settings.
 ► The study will not review studies addressing the 
initiation of aspirin for the primary prevention of car-
diovascular disease.
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(HDL) ratio and body mass index.7 The recommenda-
tions are supported by evidence from clinical trials demon-
strating the beneficial effects of lipid-lowering drugs and 
antihypertensive agents in the primary prevention of 
CVD.8–11 However, studies have reported low prescribing 
rates of preventive drugs.12–15 Patients eligible for statins 
are undertreated14 15; one study has reported that 50% 
of patients with a CVD risk ≥20% were not prescribed 
statins for primary prevention.15 In addition, the detec-
tion and treatment of hypertension remains low in parts 
of the world.16 17 Forty-nine per cent of adults with hyper-
tension aged 35–84 years were treated in Japan compared 
with 80% in the USA.16 However, the initiation rate for 
antihypertensive drugs in younger eligible adults in the 
USA is suboptimal.18 A study that explored antihyper-
tensive drug initiation among young adults with regular 
access to primary care found that only 34% of patients 
aged 18–39 years were started on antihypertensive drugs 
compared with 44% of patients aged 40–59 years.18 This 
variation in drug initiation observed across countries 
can be due to multiple factors, including health system, 
health professional and patient factors. The healthcare 
system can influence the patient's ability to access health 
services and the affordability of preventive drugs. The 
suboptimal prescribing patterns may be a result of health 
professionals’ poor adherence to guideline recommen-
dations. A study conducted in German general practices 
estimated that around 50% of general practitioners (GPs) 
did not adhere to the guidelines.19 GPs have expressed 
concerns regarding the evidence the guidelines were 
based on and whether following the guidelines will allow 
them to meet their patients’ needs.20 21 Nevertheless, 
the variation in prescribing patterns indicates that there 
are patient-related and GP-related barriers to initiating 
primary preventive treatment. Previous research identi-
fied GP-related barriers such as concerns about patient 
adherence to medication, overmedicalisation of healthy 
individuals and side effects.22 With respect to patient-re-
lated barriers, a study reported that patients preferred 
making lifestyle changes and had concerns about the 
side effects of taking medication.23 In addition, patients’ 
trust in their GP’s medical judgement played a role in 
accepting preventive treatments.23 
We are interested in studies that explore the attitudes 
of health professionals and patients towards initiating 
treatments for the primary prevention of CVD. A scoping 
search was carried out to identify existing literature and 
to estimate the volume of studies available on our topic 
of interest. The majority of published studies address 
the issue of adherence to medication or prescribing 
drugs for secondary prevention.24 25 However, the search 
retrieved a number of qualitative studies that inves-
tigate patient and health professional-related factors 
influencing drug prescribing for primary prevention. 
The search retrieved a systematic review published in 
2012 that assessed qualitative literature about initiating 
and adhering to preventive drugs for CVD. The review 
discussed factors associated with initiating preventive 
medication and reported that initiation was influenced 
by the health professional–patient relationship and the 
organisational structure of the clinical environment.26 
The authors focused on starting and adhering to preven-
tive medication with no differentiation between primary 
and secondary prevention. In addition, studies were 
excluded from the review based on quality assessment. 
Our review will consider all primary studies addressing 
our topic of interest regardless of quality to capture all 
available evidence regarding prescribing cardiovascular 
drugs for primary prevention. Furthermore, the search 
retrieved one recently published systematic review that 
explored patients’ attitudes towards taking statins. 
However, the review did not explore the attitudes of 
health professionals towards statins and was restricted to 
studies in the English language.27 The authors explored 
attitudes only towards statin uptake without differenti-
ating between primary and secondary prevention. Both 
reviews did not explore grey literature. In this review, we 
aim to explore grey literature databases to maximise the 
chances of capturing relevant studies.
Our review will add valuable information to the 
existing knowledge about CVD prevention. The existing 
reviews either assess the initiation of a specific drug, 
such as statins, or focus on the initiation of cardiovas-
cular preventive drugs without differentiating between 
primary and secondary prevention. In this review, we will 
include all preventive drugs to provide a comprehensive 
summary of evidence regarding health professionals’ 
and patients’ attitudes towards any cardiovascular drug 
recommended by the European guidelines for primary 
prevention. In addition, we chose to focus on drug 
initiation for primary prevention of CVD because the 
reasons behind taking cardiovascular preventive drugs 
such as statins might be different in patients who had 
a CVD event and patients who are yet to experience a 
CVD event. The initiation of preventive drugs in a rela-
tively asymptomatic patient can be challenging for both 
the health professional and the patient, and attitudes 
relating to this preventive approach need to be identi-
fied for successful primary care preventive prescribing. 
The decision-making process involved in initiating 
preventive treatments is complex and influenced by 
multiple factors that relate to both the health profes-
sional and the patient. Thus, an up-to-date, method-
ologically robust systematic review aiming to identify the 
attitudes and perceptions of health professionals and 
patients towards the initiation of preventive drugs for 
the primary prevention of CVD is warranted.
Objectives
 ► Explore health professionals’ attitudes and percep-
tions in relation to initiating preventive drugs for 
primary prevention of CVD in primary care settings.
 ► Explore patients’ attitudes and perceptions towards 
initiating preventive drugs for primary prevention of 
CVD in primary care settings.
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MEthOds And AnAlysIs
This protocol will use the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses Protocols (PRIS-
MA-P) guidelines to ensure comprehensive reporting 
of study items.28 The systematic review will follow the 
reporting guidelines formulated in the Enhancing 
Transparency in Reporting the Synthesis of Qualitative 
Research statement.29
Information sources and search strategy
The sample, phenomenon of interest, design, evaluation, 
research type (SPIDER) tool is considered an alternative 
to population, intervention, comparison, outcome, study 
type (PICOS) when addressing a qualitative review ques-
tion and will be used in the proposed systematic review to 
formulate the search strategy.30 The search strategy will 
include a combination of free text words and index terms 
relating to (drug initiation OR prescription OR decision 
making) and (attitudes OR experiences OR perceptions 
OR views OR behaviour) and cardiovascular disease. 
Each element from the SPIDER tool will be included in 
the search strategy and potential alternative search terms 
will be included to maximise the chances of retrieving 
relevant studies. The formulated search strategy will be 
applied to MEDLINE database (including MEDLINE In 
Process) then adapted with necessary adjustments for use 
in other databases. The search strategy for MEDLINE 
is presented in online supplementary appendix 1. We 
will search EMBASE, PsycINFO, CINAHL, and Applied 
Social Sciences Index and Abstracts for published studies. 
In addition, the following grey literature sources will 
be searched: Conference Proceedings Citation Index 
(Web of Science), Healthcare Management Informa-
tion Consortium, and Open Grey. The reference lists of 
included studies will be checked to identify additional 
eligible studies which were not retrieved by the formu-
lated search strategy. There will be no restriction on date 
or language of publication. The search will be limited to 
studies of qualitative design and mixed-methods design 
with a qualitative component.
Eligibility criteria
Sample
We will include studies of primary care health profes-
sionals (GPs and nurse practitioners), in any country, who 
prescribe cardiovascular preventive drugs. In addition, we 
will include studies that target patients who are offered 
a prescription for statins or antihypertensive drugs in a 
primary care setting. However, studies that specifically 
focus on drug initiation in older patients will not be 
included as the considerations for primary prevention 
of CVD in an older age group are different with addi-
tional factors that complicate drug prescription, such 
as multimorbidity and polypharmacy. Studies that focus 
on practitioners or patients involved in the process of 
decision-making or initiation of cardiovascular drugs will 
be included. Any study that examines practitioners who 
prescribe preventive drugs and patients who receive such 
prescriptions for secondary prevention of CVD will be 
excluded. Studies conducted in secondary care settings 
will be excluded.
Phenomenon of interest
Studies will be considered for inclusion if they assess 
patient or practitioner factors associated with the initia-
tion of cardiovascular preventive drugs in primary care 
settings. Initiation refers to the prescription of preventive 
drugs by the practitioner and the patient agreeing to take 
medication for preventive purposes. Therefore, studies 
that focus on decision-making or discuss barriers and 
facilitators to the prescription for primary prevention of 
CVD will be included. We will exclude studies that focus 
on adherence and continuation of cardiovascular preven-
tive drugs.
Design/Research type
Our review aims to look at aspects such as attitudes and 
perceptions. These are best explored through a qualita-
tive approach. Therefore, any qualitative studies, stand-
alone or in the context of a mixed-methods design, 
focusing on cardiovascular drug prescription for primary 
prevention will be included. A summary of SPIDER is 
provided in table 1.
Evaluation
Studies that address the attitudes, perceptions, views or 
experiences of health professionals or patients involved 
in the process of cardiovascular preventive drug initia-
tion will be considered for inclusion. To adhere to the 
European guidelines, we will include studies that target 
the prescription of statins or antihypertensive drugs.4 6 We 
will exclude studies that target the prescription of aspirin 
as its use for primary prevention is not recommended 
by several guidelines.5 31 In addition, studies that assess 
Table 1 Summary of sample, phenomenon of interest, 
design, evaluation, research type
Sample  ► Health professionals (general 
practitioners or nurse practitioners) 
who prescribe statins or 
antihypertensive drugs.
 ► Patients eligible for cardiovascular 
preventive drugs or offered a 
prescription of a statin or an 
antihypertensive drug for primary 
prevention of cardiovascular disease.
Phenomenon of 
interest
The initiation or prescription of statins or 
antihypertensive drugs.
Design Studies including qualitative data 
collection or analysis methods.
Evaluation Attitudes, perceptions, views or 
experiences of health professionals 
or patients related to the initiation of 
cardiovascular preventive drugs.
Research type Qualitative and mixed-methods studies.
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the attitudes and perceptions of practitioners or patients 
towards the prescribing of fibrates, niacin, bile acid 
sequestrants and omega-3 fatty acid compounds will 
be excluded as these drugs are not recommended for 
the primary prevention of CVD.4 5 In some countries, a 
polypill that contains a lipid-lowering agent and a blood 
pressure lowering agent is prescribed for CVD risk reduc-
tion.32 Thus, we will consider studies that assess health 
professionals’ and patients’ attitudes towards polypills.
selection process
The literature search results will be imported into 
Endnote V.X8 (Thomson Reuters, New York, USA), to 
ensure efficient management of references and to facil-
itate the study selection process. The process of selecting 
studies will be carried out in two stages by two indepen-
dent reviewers. The reviewers will follow explicit inclu-
sion/exclusion criteria to minimise potential bias and 
to ensure minimal influence of the reviewers’ precon-
ceptions. The inclusion/exclusion form is presented in 
online supplementary appendix 2. The first stage of selec-
tion will include screening the titles and abstracts of all 
identified records against the inclusion criteria. If a study 
addresses our topic but the abstract lacks sufficient infor-
mation to assess eligibility for inclusion, the full text will 
be retrieved to make a definitive decision. In the second 
stage of selection the two reviewers will retrieve the full 
texts of included studies and assess them for eligibility. 
Any disagreements during the selection process will be 
resolved through discussion. If the two reviewers fail to 
reach an agreement, a third independent reviewer will 
be involved for an unbiased decision. The reviewers will 
keep a record for each article that they have assessed and 
justify their decision for either inclusion or exclusion. 
The selection process will be piloted on a small number 
of studies by the main reviewer to ensure the reliability of 
the inclusion criteria. The selection process will be illus-
trated using a PRISMA flow diagram.28
data extraction process
An electronic standardised data extraction form will be 
developed to ensure adequate and consistent extraction 
of all required information. The form will be piloted 
using a small number of studies to ensure reliability and 
validity and adjusted if necessary. The electronic form will 
be used to record extracted data on study characteristics, 
participants’ details, theoretical approach, data collec-
tion methods, data analysis and findings (online supple-
mentary appendix 3). Once extraction is completed by 
the two reviewers, the forms will be reviewed, and any 
discrepancies will be resolved through discussion. If the 
two reviewers fail to reach agreement, a third reviewer 
will be involved.
Critical appraisal
Two independent reviewers will appraise the quality 
of the included studies using the Critical Appraisal 
Skills Programme Qualitative Research Checklist.33 The 
assessment of quality will be based on the study aims, 
methodology, study design, sample recruitment, reflex-
ivity, data collection, data analysis, findings, value of 
research, and ethics. The reviewers will keep a record of 
the quality assessment for each study with an explanation 
of their decision. Any disagreements will be resolved by 
discussion or referral to a third independent reviewer. 
Studies will not be excluded from the review based on 
quality.
data synthesis
The NVivo V.10 software will be used to analyse qualita-
tive data. We will adopt a method of thematic synthesis 
defined by Thomas and Harden for synthesising qual-
itative data in systematic reviews.34 Thematic synthesis 
includes three stages: First, line-by-line examination of 
studies’ findings and assigning codes to each line of text 
based on the meaning and content. Second, codes are 
then grouped into a hierarchical structure and organ-
ised as descriptive themes. Finally, analytical themes will 
be generated to provide interpretations that surpass the 
findings of the primary studies and ultimately answer our 
review question. The thematic synthesis will be carried 
out by two independent reviewers. The reviewers will 
discuss the codes and themes with an advisory team and 
then agree on the analytical stage of thematic synthesis.
Patient and public involvement
This protocol was completed without patient or public 
involvement. There were no funds or time allocated 
for patient and public involvement. Therefore, patients 
were not invited to contribute to the development of this 
protocol. There are no plans to include patients in any 
stage of this systematic review. However, the findings of 
the review will be available to healthcare professionals, 
policy-makers and the public.
dIsCussIOn
The health professional’s decision to prescribe a preven-
tive drug and the patient’s willingness to start treatment 
for preventive purposes is a multifactorial process. It is 
essential to understand this process of decision-making 
from a qualitative perspective to enable a more effective 
approach to CVD prevention. This review will summarise 
the qualitative evidence available on healthcare profes-
sionals’ and patients’ attitudes towards drug initiation. 
The findings will help us to understand the complex inter-
action that occurs during the consultation visit between 
the patient and their health professional and provide 
evidence to inform healthcare professionals and poli-
cy-makers regarding barriers and facilitators to primary 
care cardiovascular preventive prescribing.
Ethics and dissemination
This review will use information available from primary 
studies. We aim to disseminate the findings of our review 
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through publication in a peer-reviewed journal and 
presentation at a relevant conference.
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